Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$48.30 USD
-0.68 (-1.39%)
Updated May 24, 2024 04:00 PM ET
After-Market: $48.28 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 181 - 200 ( 305 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Phase III VITALITY-ALS Is a Go; Anticipating 2H15 Catalysts Next
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
R-D Day Takeaways; ALS Phase III Starting Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q15 Results; Tirasemtiv Phase III Cometh; Partnered Programs Progressing
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Upcoming R-D Day and Looking for Resurgence of Omecamtiv Interest
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Healthcare: Shaky Sector; Focus on Defined Catalysts for Remainder of 2015
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
COSMIC-HF Enrollment Complete; Data Expected in 2H15
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
FY14 Results; Taking A Deep Breath Around Upcoming Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Continuing Building Blocks Ahead with Increasing Visibility
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
More Color for Our Renewed 2015 Investment Case; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Quickly Changing Dynamic in 2015, Target Upped to $18.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.